RE:Production Capabilities Their well published, and discussed objectives are for a minimum 100% organic growth
(year over year). Paul has said many times that they seek to double their growth year over year, and that 50% of that growth is intended to come from acquisition, and 50% from organic growth.
Given the extensive acquired growth over the last six months it's difficult to say how they will be able to achieve that level of organic growth in 2022 or 2023 (it would imply they can take Ex-Tech's $30 million and turn it into $60 million by June 2023 - or sooner). This largely comes down to the cross-selling opportunities that may emerge from acquisitions like Ex-Tech.
By the way, I don't know how anyone is able to measure that they aren't already pursuing customers agressively. Just because they don't put out a press release every so often doesn't mean they aren't growing. Also, "didn't get a good answer" doesn't mean they aren't growing - it means they can't disclose insider information to an individual investor.
The Q2 financials (official) will likely provide much more insight into how we got to 12 million, and what their calculated organic growth since Q2 2020 is. I'm fairly confident that we will see close to 100% organic growth over Q2 2020. I think there has been some hints that the drop in the COVID medical packaging line may make it a bit tougher to achieve that same orgnanic growth for Q3 and Q4, but time will tell on that one.
Geochess wrote: My friend reached out to their investors relations rep and asked why they aren't pursuing customers more aggressively, didn't get a good answer but my theory was they were limited by there production capabilites. If that is the case looks like they solved it. Hoping to see a 50% increase in sales by end of the year not including from acquisitions